Group One Trading
AIMT

Group One Trading’s Aimmune Therapeutics AIMT Stock Holding History

Group One Trading’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-77,400
Closed -$2.67M – 7330
2020
Q3 		$2.67M Buy
77,400
+65,800
+567% +$1.4M 0.01% 1373
2020
Q2 		$194K Sell
11,600
-19,700
-63% -$334K ﹤0.01% 3405
2020
Q1 		$451K Buy
31,300
+28,600
+1,059% +$731K ﹤0.01% 2124
2019
Q4 		$90K Sell
2,700
-3,400
-56% -$95K ﹤0.01% 3712
2019
Q3 		$128K Buy
6,100
+5,500
+917% +$112K ﹤0.01% 3395
2019
Q2 		$12K Buy
+600
New +$12.4K ﹤0.01% 4372
2019
Q1 		– Sell
-1,000
Closed -$24K – 5643
2018
Q4 		$24K Sell
1,000
-400
-29% -$10.3K ﹤0.01% 3964
2018
Q3 		$38K Sell
1,400
-2,200
-61% -$62.2K ﹤0.01% 4125
2018
Q2 		$97K Sell
3,600
-27,600
-88% -$845K ﹤0.01% 3585
2018
Q1 		$993K Buy
31,200
+9,100
+41% +$320K 0.01% 1529
2017
Q4 		$836K Buy
+22,100
New +$713K 0.01% 1861

Group One Trading's AIMT Position: Q2 2020 in Review

Group One Trading sold out of Aimmune Therapeutics (AIMT) in Q2 2020, closing a stake of 10,617 shares — an estimated $180K sold.

Group One Trading first reported a position in AIMT in Q3 2017 and held it in 6 quarters. The position peaked at $561K in Q1 2018. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

  • Group One Trading reported no remaining Aimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Group One Trading sold 10,617 Aimmune Therapeutics shares in Q2 2020, an estimated $180K.
  • Group One Trading first reported a position in Aimmune Therapeutics in Q3 2017 and held it in 6 quarters.
  • Group One Trading's Aimmune Therapeutics position peaked at $561K in Q1 2018.
  • 165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on Group One Trading's 13F filing for Q2 2020, filed 13 Aug 2020.